Arcturus Capital Expenditures vs Depreciation Analysis

ARCT Stock

USD 17.51 0.58 3.43%

Arcturus Therapeutics financial indicator trend analysis is way more than just evaluating Arcturus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arcturus Therapeutics is a good investment. Please check the relationship between Arcturus Therapeutics Capital Expenditures and its Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arcturus Therapeutics Capital Expenditures account and Depreciation. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Arcturus Therapeutics' Capital Expenditures and Depreciation is 0.56. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Depreciation in the same time period over historical financial statements of Arcturus Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Arcturus Therapeutics' Capital Expenditures and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Arcturus Therapeutics Holdings are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Capital Expenditures i.e., Arcturus Therapeutics' Capital Expenditures and Depreciation go up and down completely randomly.

Correlation Coefficient

0.56

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Arcturus Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Arcturus Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Depreciation

Depreciation indicates how much of Arcturus Therapeutics value has been used up. For tax purposes Arcturus Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Arcturus Therapeutics Holdings must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Arcturus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arcturus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

At this time, Arcturus Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 578.5 K in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	2.7M	420K	767K	530.0K
Depreciation And Amortization	1.2M	1.5M	3.0M	3.1M

Interest Expense Depreciation And Amortization

Arcturus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Short Term Debt	Net Tangible Assets	Other Assets	Inventory
Total Assets		0.86	0.92	0.98	0.82	-0.97	-0.91	0.84	0.98	0.79	0.59	0.92	0.61	-0.25	0.95	0.66	0.99	0.92	0.81	1.0	-0.24	0.76	0.54	0.95	0.9	-0.7
Other Current Liab	0.86		0.96	0.78	0.89	-0.79	-0.86	0.7	0.85	0.86	0.38	0.81	0.44	-0.22	0.87	0.49	0.86	0.91	0.84	0.84	-0.21	0.93	0.86	0.73	0.64	-0.82
Total Current Liabilities	0.92	0.96		0.83	0.88	-0.84	-0.95	0.78	0.9	0.84	0.6	0.84	0.54	-0.22	0.95	0.59	0.93	0.99	0.84	0.91	-0.22	0.94	0.77	0.78	0.68	-0.77
Total Stockholder Equity	0.98	0.78	0.83		0.74	-0.98	-0.82	0.81	0.97	0.72	0.51	0.92	0.56	-0.25	0.88	0.61	0.95	0.83	0.73	0.98	-0.24	0.65	0.45	0.98	0.96	-0.62
Property Plant And Equipment Net	0.82	0.89	0.88	0.74		-0.67	-0.89	0.5	0.72	0.96	0.57	0.61	0.78	-0.23	0.86	0.81	0.86	0.89	0.99	0.79	-0.23	0.74	0.6	0.68	0.56	-0.97
Net Debt	-0.97	-0.79	-0.84	-0.98	-0.67		0.79	-0.91	-0.99	-0.64	-0.49	-0.97	-0.44	0.25	-0.89	-0.49	-0.92	-0.84	-0.65	-0.98	0.25	-0.71	-0.51	-0.97	-0.96	0.53
Retained Earnings	-0.91	-0.86	-0.95	-0.82	-0.89	0.79		-0.68	-0.84	-0.87	-0.75	-0.77	-0.7	0.24	-0.95	-0.75	-0.96	-0.97	-0.88	-0.89	0.23	-0.82	-0.59	-0.76	-0.65	0.8
Accounts Payable	0.84	0.7	0.78	0.81	0.5	-0.91	-0.68		0.91	0.45	0.38	0.93	0.22	-0.17	0.83	0.26	0.77	0.78	0.46	0.85	-0.16	0.75	0.51	0.8	0.83	-0.31
Cash	0.98	0.85	0.9	0.97	0.72	-0.99	-0.84	0.91		0.69	0.51	0.97	0.45	-0.26	0.92	0.51	0.94	0.89	0.69	0.99	-0.26	0.78	0.58	0.95	0.93	-0.59
Non Current Assets Total	0.79	0.86	0.84	0.72	0.96	-0.64	-0.87	0.45	0.69		0.55	0.59	0.75	-0.21	0.82	0.78	0.84	0.85	0.96	0.76	-0.21	0.7	0.58	0.66	0.52	-0.94
Non Currrent Assets Other	0.59	0.38	0.6	0.51	0.57	-0.49	-0.75	0.38	0.51	0.55		0.39	0.76	-0.25	0.67	0.79	0.67	0.68	0.62	0.58	-0.25	0.42	0.07	0.54	0.4	-0.47
Cash And Short Term Investments	0.92	0.81	0.84	0.92	0.61	-0.97	-0.77	0.93	0.97	0.59	0.39		0.29	-0.22	0.85	0.35	0.87	0.82	0.57	0.94	-0.22	0.77	0.61	0.9	0.9	-0.49
Net Receivables	0.61	0.44	0.54	0.56	0.78	-0.44	-0.7	0.22	0.45	0.75	0.76	0.29		-0.11	0.66	0.99	0.68	0.63	0.84	0.58	-0.11	0.26	-0.01	0.54	0.42	-0.75
Common Stock Total Equity	-0.25	-0.22	-0.22	-0.25	-0.23	0.25	0.24	-0.17	-0.26	-0.21	-0.25	-0.22	-0.11		-0.19	-0.18	-0.26	-0.21	-0.23	-0.24	1.0	-0.17	-0.17	-0.32	-0.25	0.28
Common Stock Shares Outstanding	0.95	0.87	0.95	0.88	0.86	-0.89	-0.95	0.83	0.92	0.82	0.67	0.85	0.66	-0.19		0.69	0.96	0.98	0.85	0.95	-0.19	0.83	0.57	0.84	0.77	-0.74
Other Current Assets	0.66	0.49	0.59	0.61	0.81	-0.49	-0.75	0.26	0.51	0.78	0.79	0.35	0.99	-0.18	0.69		0.73	0.67	0.87	0.63	-0.17	0.32	0.05	0.59	0.47	-0.78
Other Stockholder Equity	0.99	0.86	0.93	0.95	0.86	-0.92	-0.96	0.77	0.94	0.84	0.67	0.87	0.68	-0.26	0.96	0.73		0.94	0.85	0.98	-0.25	0.77	0.54	0.91	0.83	-0.76
Total Liab	0.92	0.91	0.99	0.83	0.89	-0.84	-0.97	0.78	0.89	0.85	0.68	0.82	0.63	-0.21	0.98	0.67	0.94		0.87	0.91	-0.21	0.9	0.67	0.79	0.69	-0.77
Property Plant And Equipment Gross	0.81	0.84	0.84	0.73	0.99	-0.65	-0.88	0.46	0.69	0.96	0.62	0.57	0.84	-0.23	0.85	0.87	0.85	0.87		0.77	-0.22	0.67	0.51	0.68	0.55	-0.96
Total Current Assets	1.0	0.84	0.91	0.98	0.79	-0.98	-0.89	0.85	0.99	0.76	0.58	0.94	0.58	-0.24	0.95	0.63	0.98	0.91	0.77		-0.24	0.75	0.53	0.96	0.92	-0.66
Common Stock	-0.24	-0.21	-0.22	-0.24	-0.23	0.25	0.23	-0.16	-0.26	-0.21	-0.25	-0.22	-0.11	1.0	-0.19	-0.17	-0.25	-0.21	-0.22	-0.24		-0.16	-0.16	-0.32	-0.25	0.27
Short Long Term Debt Total	0.76	0.93	0.94	0.65	0.74	-0.71	-0.82	0.75	0.78	0.7	0.42	0.77	0.26	-0.17	0.83	0.32	0.77	0.9	0.67	0.75	-0.16		0.9	0.6	0.51	-0.63
Short Term Debt	0.54	0.86	0.77	0.45	0.6	-0.51	-0.59	0.51	0.58	0.58	0.07	0.61	-0.01	-0.17	0.57	0.05	0.54	0.67	0.51	0.53	-0.16	0.9		0.39	0.31	-0.57
Net Tangible Assets	0.95	0.73	0.78	0.98	0.68	-0.97	-0.76	0.8	0.95	0.66	0.54	0.9	0.54	-0.32	0.84	0.59	0.91	0.79	0.68	0.96	-0.32	0.6	0.39		0.97	-0.56
Other Assets	0.9	0.64	0.68	0.96	0.56	-0.96	-0.65	0.83	0.93	0.52	0.4	0.9	0.42	-0.25	0.77	0.47	0.83	0.69	0.55	0.92	-0.25	0.51	0.31	0.97		-0.44
Inventory	-0.7	-0.82	-0.77	-0.62	-0.97	0.53	0.8	-0.31	-0.59	-0.94	-0.47	-0.49	-0.75	0.28	-0.74	-0.78	-0.76	-0.77	-0.96	-0.66	0.27	-0.63	-0.57	-0.56	-0.44

Click cells to compare fundamentals

Arcturus Therapeutics Account Relationship Matchups

Arcturus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	82.1M	476.5M	392.8M	450.4M	429.4M	450.9M
Other Current Liab	6.3M	17.8M	22.0M	53.7M	24.4M	25.6M
Total Current Liabilities	21.3M	49.5M	99.5M	127.0M	82.0M	86.1M
Total Stockholder Equity	25.8M	396.6M	228.2M	270.3M	278.5M	292.4M
Property Plant And Equipment Net	7.5M	8.6M	11.3M	45.0M	40.9M	43.0M
Net Debt	(51.5M)	(445.0M)	(302.9M)	(301.0M)	(261.8M)	(248.7M)
Retained Earnings	(71.7M)	(143.8M)	(347.5M)	(338.1M)	(367.9M)	(349.5M)
Accounts Payable	5.8M	10.8M	10.1M	7.4M	5.3M	3.8M
Cash	71.4M	462.9M	370.5M	391.9M	292.0M	306.6M
Non Current Assets Total	7.9M	8.7M	13.9M	47.1M	42.8M	45.0M
Cash And Short Term Investments	71.4M	462.9M	370.5M	391.9M	292.0M	156.3M
Net Receivables	2.2M	2.1M	3.4M	2.8M	32.1M	33.7M
Common Stock Total Equity	212K	214K	15K	26K	29.9K	28.4K
Common Stock Shares Outstanding	12.1M	20.3M	26.3M	27.1M	26.6M	28.0M
Liabilities And Stockholders Equity	82.1M	476.5M	392.8M	450.4M	429.4M	450.9M
Other Current Assets	758K	5.5M	10.2M	8.7M	62.5M	65.6M
Other Stockholder Equity	97.4M	540.3M	575.7M	608.4M	646.4M	678.7M
Total Liab	56.4M	79.9M	164.6M	180.1M	150.9M	158.4M
Property Plant And Equipment Gross	7.5M	8.6M	11.3M	45.0M	49.7M	52.2M
Total Current Assets	74.3M	467.8M	379.0M	403.3M	386.6M	405.9M
Common Stock	214K	15K	26K	27K	31.1K	29.5K
Short Long Term Debt Total	19.8M	17.9M	67.6M	90.9M	30.2M	32.6M
Net Tangible Assets	13.6M	25.8M	396.6M	228.2M	262.4M	275.6M
Property Plant Equipment	7.5M	3.4M	11.3M	45.0M	51.7M	54.3M
Capital Surpluse	58.3M	97.4M	540.3M	575.7M	662.0M	695.1M
Other Liab	15.2M	12.5M	19.9M	22.9M	26.3M	14.0M
Current Deferred Revenue	8.4M	18.1M	43.5M	28.6M	47.3M	49.7M
Non Current Liabilities Total	35.0M	30.4M	65.1M	53.1M	68.9M	38.6M
Net Invested Capital	40.8M	411.6M	291.3M	331.0M	278.5M	221.7M
Net Working Capital	53.0M	418.3M	279.4M	276.3M	304.6M	220.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC